These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

51 related articles for article (PubMed ID: 21747238)

  • 1. Reducing tuberculosis-associated early mortality in antiretroviral treatment programmes in sub-Saharan Africa.
    Lawn SD; Harries AD
    AIDS; 2011 Jul; 25(12):1554-5; author reply 1556. PubMed ID: 21747238
    [No Abstract]   [Full Text] [Related]  

  • 2. Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality?: did close examination of the trees obscure our view of the wood?
    Grant AD; Fielding KL; Charalambous S; Chaisson RE; Churchyard GJ
    AIDS; 2010 Nov; 24 Suppl 5():S15-8. PubMed ID: 21079423
    [No Abstract]   [Full Text] [Related]  

  • 3. [Severe opportunistic infections in HIV-positive adults in sub-Saharan Africa].
    Anglaret X
    Med Trop (Mars); 2006 Aug; 66(4):343-5. PubMed ID: 16999042
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reducing mortality from HIV infection and tuberculosis.
    Koole O; Colebunders R
    Lancet Infect Dis; 2011 Jul; 11(7):494-5. PubMed ID: 21514235
    [No Abstract]   [Full Text] [Related]  

  • 5. Mortality by baseline CD4 cell count among HIV patients initiating antiretroviral therapy: evidence from a large cohort in Uganda.
    Mills EJ; Bakanda C; Birungi J; Mwesigwa R; Chan K; Ford N; Hogg RS; Cooper C
    AIDS; 2011 Mar; 25(6):851-5. PubMed ID: 21330903
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contemporary treatment of tuberculosis in HIV prevalent countries in sub-Saharan Africa.
    Nuwaha F
    East Afr Med J; 1998 Jun; 75(6):358-63. PubMed ID: 9803621
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiretroviral therapy in sub-Saharan Africa: adherence lessons from tuberculosis and leprosy.
    Reid SE; Reid CA; Vermund SH
    Int J STD AIDS; 2004 Nov; 15(11):713-6. PubMed ID: 15537453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival of a large cohort of HIV-infected tuberculosis patients in the era of highly active antiretroviral treatment.
    Català L; Orcau A; García de Olalla P; Millet JP; Rodríguez-Mondragón A; Caylà JA;
    Int J Tuberc Lung Dis; 2011 Feb; 15(2):263-9, i. PubMed ID: 21219692
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of tuberculosis cotreatment on viral suppression rates among HIV-positive children initiating HAART.
    Zanoni BC; Phungula T; Zanoni HM; France H; Feeney ME
    AIDS; 2011 Jan; 25(1):49-55. PubMed ID: 20935555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [AIDS treatment in Africa: the risk of antiretroviral resistance].
    Hamers RL; Schuurman R; van Vugt M; Derdelinckx I; Rinke de Wit TF
    Ned Tijdschr Geneeskd; 2007 Dec; 151(48):2666-71. PubMed ID: 18179083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Highly active antiretroviral therapy and tuberculosis control in Africa: synergies and potential.
    Harries AD; Hargreaves NJ; Chimzizi R; Salaniponi FM
    Bull World Health Organ; 2002; 80(6):464-9. PubMed ID: 12132003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa.
    Hamers RL; Derdelinckx I; van Vugt M; Stevens W; Rinke de Wit TF; Schuurman R;
    Antivir Ther; 2008; 13(5):625-39. PubMed ID: 18771046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human immunodeficiency virus-1 RNA levels and CD4 lymphocyte counts, during treatment for active tuberculosis, in South African patients.
    Morris L; Martin DJ; Bredell H; Nyoka SN; Sacks L; Pendle S; Page-Shipp L; Karp CL; Sterling TR; Quinn TC; Chaisson RE
    J Infect Dis; 2003 Jun; 187(12):1967-71. PubMed ID: 12792875
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Seven-year experience of a primary care antiretroviral treatment programme in Khayelitsha, South Africa.
    Boulle A; Van Cutsem G; Hilderbrand K; Cragg C; Abrahams M; Mathee S; Ford N; Knight L; Osler M; Myers J; Goemaere E; Coetzee D; Maartens G
    AIDS; 2010 Feb; 24(4):563-72. PubMed ID: 20057311
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of antituberculosis treatment on virological response to highly active antiretroviral therapy: implications for resource-limited settings?
    Lawn SD; Wood R
    J Infect Dis; 2006 Nov; 194(10):1467-8; author reply 1468. PubMed ID: 17054078
    [No Abstract]   [Full Text] [Related]  

  • 16. HIV-associated tuberculosis: clinical update.
    Swaminathan S; Padmapriyadarsini C; Narendran G
    Clin Infect Dis; 2010 May; 50(10):1377-86. PubMed ID: 20388036
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemoprophylaxis for tuberculosis in HIV-infected individuals in sub-Saharan Africa.
    Nuwaha F
    East Afr Med J; 1998 Sep; 75(9):520-7. PubMed ID: 10493054
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lack of appropriate treatment for people with comorbid HIV/AIDS and epilepsy in sub-Saharan Africa.
    Birbeck G; Chomba E; Ddumba E; Kauye F; Mielke J
    Epilepsia; 2007 Jul; 48(7):1424-5. PubMed ID: 17635568
    [No Abstract]   [Full Text] [Related]  

  • 19. New South Africa Institute to tackle HIV and TB.
    McEnery R
    IAVI Rep; 2009; 13(3):15. PubMed ID: 20214318
    [No Abstract]   [Full Text] [Related]  

  • 20. Antiretroviral drugs for tuberculosis control in the era of HIV/AIDS.
    Williams BG; Dye C
    Science; 2003 Sep; 301(5639):1535-7. PubMed ID: 12920302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.